The US proteases market is experiencing robust growth, driven by increasing applications in pharmaceuticals, food processing, and biotechnology sectors. As key industrial enzymes, proteases play a crucial role in protein processing, clinical diagnostics, and therapeutic development, making them vital for multiple high-growth industries. The market size was valued at USD 520 million in 2025 and is projected to reach USD 1,200 million by 2035, expanding at a CAGR of 8.1% from 2024 to 2035.
The economic impact of tariffs on "US Proteases Market".
Market Growth Drivers
Expanding Applications in Pharmaceuticals: The pharmaceutical sector is embracing proteases owing to their crucial role in drug formulation, wound debridement, and anticancer therapy. Major players like Genencor, a division of DuPont, have intensified R&D expenditures to tailor protease formulations for novel drug delivery systems, thus driving market growth.
Growing Demand in the Food Industry: Proteases are widely used in protein hydrolysis, baking, and dairy processing. Companies such as Novozymes have introduced enzyme solutions that enhance yield, texture, and nutritional profiles in food products, responding to increased consumer demand for natural and clean-label ingredients.
Market Trends
Integration of Artificial Intelligence in Enzyme Engineering: The emergence of AI-powered tools for enzyme design is transforming the development and optimization of proteases. Companies including Codexis are leveraging machine learning to enhance enzyme activity, specificity, and stability, enabling rapid innovation and commercialization.
Focus on Sustainable and Non-Animal Protease Production: With rising concerns regarding environmental impact, companies such as DSM are emphasizing sustainable fermentation-based production methods for proteases. This trend aligns with the broader industry shift toward green chemistry and circular bioeconomy principles.
Market Opportunities
Expansion in Therapeutic Proteases: There is a significant opportunity for companies like Merck & Co. to develop therapeutic proteases for rare diseases and targeted cancer therapies, addressing unmet clinical needs.
Advancements in Personalized Medicine: The integration of protease profiling in personalized diagnostics offers tremendous growth potential for companies such as Thermo Fisher Scientific.
The US proteases market demonstrates a strong and consistent growth trajectory from 2020 to 2035. Starting at USD 290 million in 2020, the market has witnessed a compound annual growth rate (CAGR) of approximately 8.1%, reaching a projected value of USD 1,200 million by 2035. The upward trend is fueled by expanding protease applications across pharmaceuticals, food, and biotechnology sectors. Major investments from key companies and a shift toward sustainable manufacturing practices have propelled revenue growth. The market is expected to continue this momentum as advanced enzyme engineering technologies and new therapeutic uses emerge. The chart below visualizes this steady revenue increase over the forecast period.
US Proteases Market by Region Share (%) in 2025
In 2025, the US proteases market is notably dominated by the Midwest region, holding 36% of total market share, driven by its thriving food processing and biotechnology industries. The West follows with a 24% share, owing to a concentration of biotech startups and innovation hubs. The South constitutes 18%, propelled by the presence of key pharmaceutical manufacturers. The Northeast, known for its prominent academic and research institutions, accounts for 16%. Other regions combine for the remaining 6%. This distribution underscores the diverse regional growth drivers across the US proteases market, with the Midwest retaining a leading position.
Recent Market Developments (Last 6 Months)
In April 2024, Novozymes announced the launch of a next-generation food-grade protease designed to improve protein hydrolysis efficiency in plant-based meats. The innovation, featuring enhanced thermostability and neutral pH performance, helps food manufacturers achieve improved texture and nutrient profiles. Several major food processors in the US have already adopted this enzyme in pilot production.
In May 2024, Codexis expanded its collaboration with a leading US-based biotechnology firm to co-develop AI-optimized proteases for next-generation biotherapeutics. The partnership is expected to accelerate the development of enzyme-based drugs with superior efficacy and reduced immunogenicity, following recent positive preclinical data.
In June 2024, DSM completed the acquisition of a US-based microbial fermenter company to advance sustainable protease production. The integration is aimed at scaling eco-friendly protease manufacturing, reducing carbon footprint, and broadening DSM’s enzyme portfolio for various industrial sectors including food, feed, and pharmaceuticals.
By Type (Serine Protease, Metalloprotease, Cysteine Protease, Aspartic Protease, Threonine Protease, Other Protease); By Application (Pharmaceuticals, Food & Beverage, Animal Feed, Diagnostics, Detergents, Others); By Distribution Channel (Online, Offline, Direct Tenders, Third Party Distributors, E-Commerce, Others); By Technology (Microbial, Plant-Based, Animal-Based, Recombinant, Fermentation, Others); By Organization Size (Small, Medium, Large)
Press Releases